ATOSSA THERAPEUTICS, INC.
No enriched coverage for $ATOS in the last 7 days.
No SEC Form 4 filings for $ATOS in the last 30 days.
See all $ATOS insider activity →According to an analysis of Atossa Therapeutics (NASDAQ:ATOS), the company had about $26m cash and no debt as of June 2026. Its last-year cash burn was about $36m, implying a cash runway of roughly 9 months. The article also says cash burn rose 43% year over year and cash burn exceeded market cap.
Atossa Therapeutics (Nasdaq: ATOS) reported second-quarter 2026 results for the quarter ended June 30, 2026 and provided a corporate update. The company highlighted scientific updates for (Z)-endoxifen in rare pediatric diseases and ER+ breast cancer, including EVANGELINE Phase 2 progress. Atossa also completed a registered direct offering raising $4.5 million upfront, with potential gross proceeds up to $16.5 million.
ATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, WASHINGTON, August 7, 2026 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncol
Recent ATOS coverage spans financial news, corporate actions and earnings.
Rising cash burn versus limited cash suggests elevated dilution or financing risk, which can pressure equity risk premium.
The capital raise and ongoing (Z)-endoxifen clinical and preclinical updates are likely to support near-term sentiment, but dilution risk can cap upside.
The filing combines operating expense updates with a fresh equity financing and new (Z)-endoxifen conference and publication catalysts, which can shift near-term funding and sentiment risk.
The arrest and termination narrative raises reputational and governance risk for ATOS, but the filing says no material business effect due to short tenure.
The filing signals a new equity-linked financing/issuance arrangement, which can be dilutive and may affect near-term liquidity and capital structure expectations.
alphai scores every news story that mentions ATOS with an AI model for sentiment and relevance, and aggregates insider trades from ATOSSA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
According to an analysis of Atossa Therapeutics (NASDAQ:ATOS), the company had about $26m cash and no debt as of June 2026. Its last-year cash burn was about $36m, implying a cash runway of roughly 9 months. The article also says cash burn rose 43% year over year and cash burn exceeded market cap.
6 min readAtossa Therapeutics (Nasdaq: ATOS) reported second-quarter 2026 results for the quarter ended June 30, 2026 and provided a corporate update. The company highlighted scientific updates for (Z)-endoxifen in rare pediatric diseases and ER+ breast cancer, including EVANGELINE Phase 2 progress. Atossa also completed a registered direct offering raising $4.5 million upfront, with potential gross proceeds up to $16.5 million.
6 min readATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update SEATTLE, WASHINGTON, August 7, 2026 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncol
6 min readAccording to Stat News and an SEC filing by California-based Immix Biopharma, Richard Graydon, an alias for fugitive Ronald Fischer, was arrested July 16 in New York after 20 years on the run. Immix said it terminated Graydon on Friday for reasons unrelated to company activities and expects no material business impact. Atossa previously hired him as interim CMO.
7 min readATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 atos-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 10, 2026, between Atossa Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on
6 min readAtossa Genetics Inc. (NASDAQ:ATOS) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $6.33. The biotechnology company, focused on breast cancer therapeutics, currently trades around $0.65. Institutional ownership stands at approximately 12.74%, with notable recent increases from firms like Bank of America and Qube Research & Technologies.
3 min readAtossa Therapeutics (ATOS) has received Orphan Drug Designation from the FDA for its drug candidate, Z-endoxifen, for treating Duchenne muscular dystrophy. This designation is a significant step for the clinical-stage biopharmaceutical company, which focuses on unmet medical needs in oncology. Despite facing challenges in revenue growth and profitability, Atossa demonstrates strong financial health with no debt and high liquidity, suggesting resilience against potential setbacks.
4 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
3 min readHere is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
4 min readSEATTLE, April 22, 2025 ( GLOBE NEWSWIRE ) -- Atossa Therapeutics, Inc. ( Nasdaq: ATOS ) ( "Atossa" or the "Company" ) , a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office ( USPTO ) has ...
2 min read
